Istesso Limited

Istesso Limited is a biopharmaceutical company based in London, United Kingdom. Rather than organising drug discovery around individual disease labels, Istesso frames its work around what it describes as "conserved adaptive systems" — the biological machinery that senses stress, enables repair and restores function. The company's stated thesis is that the next era of medicine will not simply manage diseases one by one, but will instead "build health" by restoring the underlying biology that enables repair. Istesso's therapeutic approach centres on oral mitochondrial Complex I modulators (MCMs). These are systemic small-molecule medicines intended to restore the capacity of tissues to sense stress, adapt and repair. The company describes this as "one biology, multiple tissues" — a platform approach in which a single conserved mechanism may be relevant across a range of tissues and conditions. Its lead programme, leramistat, is reported to be in Phase 2 clinical development, supported and enabled by what the company calls its adaptive repair platform. Beyond its clinical pipeline, Istesso publishes market and landscape analysis on conditions it considers underserved. Publicly highlighted areas include sarcopenia — the progressive loss of skeletal muscle mass, strength and physical performance with aging or chronic disease — which the company describes as one of the largest remaining untapped pharmaceutical markets, affecting tens of millions of adults worldwide and driving substantial healthcare costs through falls, frailty, loss of independence and increased mortality. The company also publishes commentary on the broader regenerative medicine field. Istesso presents itself as a platform-stage biopharmaceutical company rather than a commercial-stage pharmaceutical manufacturer. Its public communications emphasise scientific rationale, pipeline progress and market opportunity rather than marketed products. The company is headquartered in London and operates in the biopharmaceutical research and development sector. Detailed public information on its founding, ownership structure, financing and executive leadership is limited in the available evidence.

Istesso Limited is a biopharmaceutical company headquartered in London, United Kingdom. Publicly available evidence describes it as a company in London, United Kingdom, and its own website presents it as a platform-stage drug developer rather than a commercial-stage pharmaceutical manufacturer. The company's scientific premise is a critique of how medicine has historically been organised. In Istesso's framing, medicine has for decades organised biology into diseases — "thousands of labels, targets and fragmented solutions" — even though biology itself is not organised that way. Istesso argues that health depends on conserved adaptive systems that sense stress, enable repair and restore function. Its stated ambition is to help bring about a next era of medicine that "builds health" by asking how to restore the biology that enables repair, rather than how to manage another disease. Istesso's therapeutic strategy is built on oral mitochondrial Complex I modulators (MCMs). These systemic medicines are intended to restore the capacity of tissues to sense stress, adapt and repair. The company summarises the approach as "one biology, multiple tissues," implying that a single conserved mechanism could have relevance across multiple tissue types and conditions. Its lead programme, leramistat, is described as being in Phase 2, supported and enabled by the company's adaptive repair platform. Alongside its pipeline, Istesso publishes analysis of markets and landscapes it considers strategically important. One such document addresses sarcopenia, defined as the progressive loss of skeletal muscle mass, strength and physical performance with aging or chronic disease. Istesso describes sarcopenia as one of the largest remaining untapped pharmaceutical markets, affecting tens of millions of adults worldwide and driving enormous healthcare costs through falls, frailty, loss of independence and increased mortality. The company also publishes broader commentary on regenerative medicine, including a piece titled "How to Make a Regenerative Medicine." Detailed corporate history — including founding date, founders, financing rounds, ownership and leadership — is not available in the supplied evidence. The company's public identity is therefore best characterised as an active, privately held, London-based biopharmaceutical research and development company pursuing a platform approach to adaptive repair.

• Istesso's lead programme leramistat reaches Phase 2 clinical development, supported by the company's adaptive repair platform.

  [1]Istesso – Activating Adaptive Repairistesso.co.uk
• Istesso publishes a market and landscape document on sarcopenia.

  [1]Istesso – Activating Adaptive Repairistesso.co.uk
• Istesso publishes commentary titled "How to Make a Regenerative Medicine."

  [1]Istesso – Activating Adaptive Repairistesso.co.uk

Platform-stage biopharmaceutical company focused on activating conserved adaptive repair biology through oral mitochondrial Complex I modulators, positioning itself around "building health" rather than managing individual diseases.

• Leramistat

  Istesso's lead clinical programme, described as being in Phase 2 and supported by the company's adaptive repair platform.

• Oral mitochondrial Complex I modulators (MCMs)

  Systemic small-molecule medicines intended to restore the capacity of tissues to sense stress, adapt and repair.

1. 1Istesso – Activating Adaptive Repairistesso.co.uk
2. 2Istesso Limited (United Kingdom) – Wikidatawikidata.org